DORZOLAMIDE-TIMOLOL SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

TIMOLOL (TIMOLOL MALEATE); DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE)

Pieejams no:

MICRO LABS LIMITED

ATĶ kods:

S01ED51

SNN (starptautisko nepatentēto nosaukumu):

TIMOLOL, COMBINATIONS

Deva:

5MG; 20MG

Zāļu forma:

SOLUTION

Kompozīcija:

TIMOLOL (TIMOLOL MALEATE) 5MG; DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20MG

Ievadīšanas:

OPHTHALMIC

Vienības iepakojumā:

100

Receptes veids:

Prescription

Produktu pārskats:

Active ingredient group (AIG) number: 0237301001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2022-06-23

Produkta apraksts

_Page 1 of 37_
_DORZOLAMIDE-TIMOLOL (Dorzolamide Hydrochloride and Timolol Maleate
Ophthalmic Solution)_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DORZOLAMIDE-TIMOLOL
Dorzolamide
Hydrochloride and Timolol Maleate Ophthalmic Solution
Ophthalmic Solution, 20 mg / mL dorzolamide (as dorzolamide
hydrochloride) and 5 mg / mL
timolol (as timolol maleate)
USP
Elevated Intraocular Pressure Therapy
Topical Carbonic Anhydrase Inhibitor and Topical Beta-Adrenergic
Blocking Agent
Manufactured by:
Date of Initial Approval:
Micro Labs Limited
June 16, 2022
Bangalore– 560001
INDIA
Canadian Importer/Distributor:
13187811
Canada Inc.
Mississauga, ON L4Z 1S1
Submission Control Number: 250138
_Page 2 of 37_
_DORZOLAMIDE-TIMOLOL (Dorzolamide Hydrochloride and Timolol Maleate
Ophthalmic Solution)_
RECENT MAJOR LABEL CHANGES
Not applicable.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
....................................................................................................
4
1.1
Pediatrics
................................................................................................
4
1.2
Geriatrics
................................................................................................
4
2
CONTRAINDICATIONS.......................................................................................
4
4
DOSAGE AND ADMINISTRATION
......................................................................
5
4.1
Dosing Considerations
.............................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............